GlassScriptPhysician profile
Richard M Bianco
NPI 1649355991
$466.25
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $392 · 2021: $74.27.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $83.05 | 2019 | |
| Abbvie INC. | $74.27 | 2021 | |
| Janssen Pharmaceuticals, INC | $60.31 | 2019 | |
| Amarin Pharma, INC. | $50.83 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.12 | 2019 | |
| Genentech USA, INC. | $42.24 | 2019 | |
| Pfizer INC. | $28.07 | 2019 | |
| Melinta Therapeutics, LLC | $20.12 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $18.15 | 2019 | |
| Sanofi Pasteur INC. | $17.31 | 2019 | |
| Novo Nordisk INC | $14.73 | 2019 | |
| Lilly USA, LLC | $13.05 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Bianco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.